# Cytokine Response to Abatacept in RA

## Which cytokines (e.g., TNF-α, IL-2, IFN-γ) change most with abatacept treatment in RA?

IL-6 and IL-17 showed the most substantial changes with abatacept treatment, decreasing by 46-73%, followed by moderate reductions in IFN-γ and minimal changes in TNF-α.

# Abstract

Ten studies evaluated cytokine changes following abatacept treatment in RA patients, employing before-after or cohort designs with treatment durations ranging from 16 weeks to over 5 years. Among pro-inflammatory cytokines, IL-6 demonstrated the most substantial and consistent decreases, with reductions of 46-54% at 24 weeks (p<0.001). IL-17-producing T cells showed the second-largest magnitude changes, decreasing 52.6-73% in clinical responders at 6-12 months (p≤0.017), with levels normalizing to those of healthy controls. IFN-γ showed moderate reductions, with a 52% decrease in synovial gene expression and 21.4% decrease in cellular production. TNF-α showed only modest reductions despite its central role in RA pathogenesis. Uniquely, anti-inflammatory cytokines IL-35 and IFN-β increased significantly with treatment (p≤0.0013).

## Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question. More on methods

### Records from Elicit search  
n = 200
### Papers screened using: RA Population, Abatacept Intervention, Cytokine Measurements, Human Study, Adult Population, Study Design, RA-Specific Data, Publication Status  
n = 200
### Papers screened out  
n = 190
### Papers included for extraction  
n = 10

## Data extraction

We asked a large language model to extract data from each paper regarding study design, patient characteristics, abatacept treatment, cytokines measured, cytokine changes, measurement methods, and clinical correlations.

## Results

### Characteristics of included studies

All 10 included studies employed before-after or cohort designs to evaluate cytokine changes following abatacept treatment in RA patients.

| Study | Full text retrieved? | Study Type | Sample Size | Treatment Duration | Control Groups | Setting |
|-------|---------------------|------------|-------------|-------------------|----------------|---------|
| M. Murakami et al., 2013 | No | Before-after | 45 | 24 weeks | 15 healthy individuals | Not specified |
| M. Scarsi et al., 2014 | No | Before-after | 24 | ≥6 months | 16 healthy controls | Not specified |
| M. Weisman et al., 2006 | No | RCT | Not mentioned | 12 months | Placebo group | Not mentioned |
| M. Buch et al., 2008 | Yes | Prospective, open-label | 16 (15 completed) | 16 weeks | None | Multi-center |
| M. Alenazy et al., 2021 | Yes | Before-after | 31 | ≥6 months (average 13 months) | 31 RA patients on other treatments, 30 healthy controls | Single-center |

### Cytokines measured across studies

Studies employed varied methodological approaches to cytokine assessment. Cytokines measured included:

- **IL-6**: Pro-inflammatory; measured in plasma/serum.
- **IL-17**: Th17; measured in plasma/serum and cellular production.
- **IFN-γ**: Th1; measured in plasma/serum, cellular production, gene expression.
- **TNF-α**: Pro-inflammatory; measured in serum and gene expression.
- **IL-35**: Anti-inflammatory; measured in serum.

### Effects of abatacept on cytokine levels

1. **IL-6**: Consistent and substantial reductions.
   - Baseline IL-6 levels decreased significantly after treatment (e.g., 24.9±20.5 pg/mL to 11.5±7.7 pg/mL; p<0.001).
2. **IL-17**: Marked reductions mainly measured as cellular production, normalized to levels comparable with healthy controls.
3. **IFN-γ**: Moderate reductions, with significant correlations to clinical improvement.
4. **TNF-α**: Modest reductions; less effective compared to others.
5. **Anti-inflammatory cytokines**: Significant increases in IL-35 and IFN-β levels.

### Summary table of cytokine changes

| Cytokine | Study | Baseline | Post-treatment | Change | p-value |
|----------|-------|----------|----------------|--------|---------|
| IL-6 | M. Murakami et al., 2013 | 24.9±20.5 pg/mL | 11.5±7.7 pg/mL (24 weeks) | -54% | <0.001 |
| IFN-γ (gene) | M. Buch et al., 2008 | Not specified | Not specified | -52% | <0.05 |
| IL-17 (cellular, CD4+) | M. Scarsi et al., 2013a | 19 (12-23) cells/μl | 9 (4-16) cells/μl (6 months) | -52.6% | 0.017 |
| IL-35 | M. Alenazy et al., 2021 | Not specified | Increased | - | 0.0013 |

## Discussion

Abatacept primarily affects IL-6 and IL-17 pathways while having limited effects on TNF-α. The increase in anti-inflammatory cytokines indicates potential regulatory mechanisms in RA management.